PDS Biotech (PDSB)

[lidopete]

TheFly.com

Portfolio Alerts
Click the Portfolio Name or Symbol to see the research on thefly.com
Main Portfolio matches: PDSB.

TODAY, JUNE 09, 2021
PDSB
07:05
Recommendations
PDS Biotechnology price target raised to $18 from $6.50 at Alliance Global Partners
Alliance Global Partners analyst James Molloy raised the firm's price target on PDS Biotechnology to $18 from $6.50 and keeps a Buy rating on the shares after the company reported additional data from its ongoing PDS0101 Phase 2 triple combination trial in HPV-related cancers at ASCO. He has lowered his discount rate on expected future royalty payments and is now including a separate valuation for PDSB0101 given the recent promising HPV triple combination data and "promising results" from PDS' proprietary Versamune platform, Molloy tells investors.